Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agenus Inc. (NASDAQ: AGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded immuno-oncology developer. As a filer under the Securities Exchange Act of 1934, Agenus uses Forms 8-K, 10-Q, 10-K and proxy materials to report financial results, clinical and corporate milestones, and shareholder actions related to its cancer immunotherapy programs.
Recent Form 8-K filings illustrate how these documents track material events. Agenus has furnished quarterly financial results for periods in 2025, reported on its annual meeting of stockholders and voting outcomes on director elections and equity plans, and described a promissory note agreement with a Zydus Lifesciences subsidiary tied to the planned sale of its Emeryville and Berkeley biologics manufacturing facilities. Other 8-Ks outline progress on the broader asset purchase, stock purchase and license agreements with Zydus, including updates on the Committee on Foreign Investment in the United States (CFIUS) review process.
For investors analyzing Agenus, periodic reports such as Forms 10-Q and 10-K (when available) are central to understanding the company’s financial condition, risk factors and research and development focus in immuno-oncology. These filings typically discuss the BOT+BAL clinical program, broader pipeline of antibody therapeutics, adoptive cell therapies and adjuvants, and the company’s development capabilities and collaborations.
On Stock Titan, each new Agenus filing is captured from EDGAR and paired with AI-powered summaries designed to highlight the most important points—such as key terms of financing arrangements, updates on the Zydus collaboration, or changes in capital structure. Users can also review Forms 4 and related ownership reports to monitor insider transactions in AGEN shares. This centralized view helps readers navigate complex SEC documents and quickly identify information relevant to Agenus’ immuno-oncology strategy, clinical progress and corporate governance.
AGENUS INC director Susan B. Hirsch received a grant of stock options to acquire 105,000 shares of Common Stock. The options have an exercise price of $3.90 per share and were awarded at no cost as a compensation grant.
The award was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on the one-year anniversary of the grant date. Following this grant, Hirsch holds stock options covering 105,000 underlying shares directly, with an expiration date in 2036.
AGENUS INC director and officer Jennifer Buell received new stock option awards as part of her equity compensation. On April 24, she was granted options to acquire 5,000 shares of common stock and a separate grant covering 300,000 shares, both with an exercise price of $3.90 per share and expiring on April 24, 2036.
The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years. One-third of each award vests on April 24, 2027, with the remaining two-thirds vesting in equal quarterly installments thereafter. These are compensation-related grants rather than open-market purchases or sales.
AGENUS INC Chief Medical Officer Steven J. O'Day received two stock option awards covering a total of 165,333 shares of common stock. Both option grants have an exercise price of $3.90 per share and expire on April 24, 2036.
One option for 95,333 shares was awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments thereafter. A second option for 70,000 shares was granted under the same plan in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026.
AGENUS INC director Thomas L. Harrison received a compensation-related stock option grant rather than making an open-market trade. On the grant date, he was awarded options to acquire 122,500 shares of Common Stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The filing shows he holds options for 122,500 shares after this grant, and a footnote explains the award was made under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on the one-year anniversary of the grant date.
AGENUS INC director Timothy Wright received a stock option grant as equity compensation. The award covers 105,000 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The option was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests on the one-year anniversary of the grant date. Following this grant, Wright holds stock options for 105,000 underlying shares directly.
AGENUS INC principal accounting officer Austin Charette received two stock option awards as compensation. On April 24, 2026, Charette was granted options to purchase 17,619 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. These options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments.
Charette also received an additional option grant covering 5,000 shares of common stock at the same $3.90 exercise price, also expiring on April 24, 2036. This second grant was awarded in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026. Both transactions are compensation-related grants, not open-market purchases or sales.
Agenus Inc. director and officer Armen Garo H received three stock option awards on April 24, 2026. Each option allows him to purchase Agenus common stock at an exercise price of $3.90 per share and expires on April 24, 2036. One award is scheduled to vest over three years beginning April 24, 2027, and another was granted in lieu of his 2025 annual cash bonus and will vest in full on May 24, 2026.
Agenus Inc. director Brian Corvese received a grant of 210,000 stock options for Agenus Inc. common stock. The options were awarded on April 24, 2026 under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan at an exercise price of $3.90 per share.
The award vests on the one-year anniversary of the grant date and expires on April 24, 2036. After this grant, Corvese holds 210,000 stock options directly. This is a compensation-related award rather than an open-market share purchase or sale.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 3,403 shares of Common Stock as compensation for his salary for the pay period ending April 17, 2026. His salary is being paid in stock, in lieu of cash, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and these shares are fully vested on the date of issuance.
The shares were valued at $4.79 per share, the closing price of Agenus Common Stock on April 17, 2026. After this grant, Dr. Armen directly holds 342,550 shares, and he also has indirect holdings through IRA accounts and trusts/partnerships, where he has varying degrees of investment authority and pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 3,403 shares of Common Stock as compensation for his salary for the pay period ending April 17, 2026. His salary is being paid in stock, in lieu of cash, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and these shares are fully vested on the date of issuance.
The shares were valued at $4.79 per share, the closing price of Agenus Common Stock on April 17, 2026. After this grant, Dr. Armen directly holds 342,550 shares, and he also has indirect holdings through IRA accounts and trusts/partnerships, where he has varying degrees of investment authority and pecuniary interest.
Agenus Inc. seeks stockholder approval of equity proposals while summarizing 2025–early 2026 clinical, commercial and financial progress. Management highlights durable BOT+BAL survival data presented at ESMO, reimbursed compassionate-access revenues recognized in France, enrollment start of the registrational Phase 3 BATTMAN trial, and a transaction that improved liquidity.
The proxy asks for (i) a 5,000,000-share increase to the 2019 Equity Incentive Plan and (ii) a one-time option exchange with executive/director replacement options struck at 150% of the exchange-date market price. The CEO urges support to preserve the team and continue BATTMAN, expanded access, and regulatory engagement.